electroCore, Inc. (ECOR)

NASDAQ: ECOR · IEX Real-Time Price · USD
0.538
-0.058 (-9.69%)
At close: Jun 24, 2022 4:00 PM
0.535
-0.003 (-0.632%)
After-hours: Jun 24, 2022 7:58 PM EDT
-9.69%
Market Cap 38.10M
Revenue (ttm) 6.15M
Net Income (ttm) -17.42M
Shares Out 70.77M
EPS (ttm) -0.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 286,170
Open 0.596
Previous Close 0.596
Day's Range 0.538 - 0.608
52-Week Range 0.265 - 1.680
Beta 1.04
Analysts Buy
Price Target 2.86 (+431.2%)
Earnings Date Aug 4, 2022

About ECOR

electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaw... [Read more...]

Industry Health Care Equipment & Supplies
IPO Date Jun 22, 2018
CEO Daniel Goldberger
Employees 52
Stock Exchange NASDAQ
Ticker Symbol ECOR
Full Company Profile

Financial Performance

In 2021, electroCore's revenue was $5.45 million, an increase of 55.93% compared to the previous year's $3.50 million. Losses were -$17.22 million, -26.77% less than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for ECOR stock is "Buy." The 12-month stock price forecast is 2.86, which is an increase of 431.20% from the latest price.

Price Target
$2.86
(431.20% upside)
Analyst Consensus: Buy
Stock Forecasts

News

electroCore, Inc. Announces gammaCore™ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain ...

ROCKAWAY, N.J., May 24, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the gammaCore Sapphire™ non-invasive vagus nerv...

electroCore to Participate at Upcoming Investor Conferences

ROCKAWAY, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore's Chief Executive Officer, Dan Gold...

electroCore Announces Record First Quarter 2022 Financial Results

First quarter 2022 net sales of $1.9 million, approximately 58% over first quarter 2021 and 27% sequentially

electroCore Completes Sale of New Jersey Tax Benefits

ROCKAWAY, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has completed the sale of its available ta...

electroCore Announces Publication of Investigator-Initiated Trial Data for SAVIOR-1 in COVID-19 Patients in Frontiers...

ROCKAWAY, N.J., April 21, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Frontiers in Neurology has published results ...

gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) Selected for Department of Defense Biotech Optimized for Opera...

ROCKAWAY, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore™ nVNS has been selected for further...

electroCore Announces Dr. Peter Staats to Keynote the Fifth Annual Bioelectronic Medicine Forum in New York

ROCKAWAY, N.J., March 23, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced its co-founder and Chief Medical ...

electroCore to Present at 2022 Maxim Virtual Growth Conference

ROCKAWAY, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore's Chief Executiv...

electroCore Announces Fourth Quarter and Full Year 2021 Financial Results

Full year 2021 net sales of approximately $5.5 million increased 56% over $3.5 million for full year 2020

electroCore Announces Changes to its Board of Directors

Julie Bruzzone Goldstein and Tricia Wilber to join the Board, adding significant marketing, media and brand strategy experience Julie Bruzzone Goldstein and Tricia Wilber to join the Board, adding signi...

electroCore to Present at 34th Annual Roth Conference

ROCKAWAY, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will be ...

electroCore, Inc. Announces Three Abstracts to be Presented at International Stroke Conference 2022

Clinical Research Conducted on Non-invasive Vagus Nerve Stimulation (nVNS) for the Acute Treatment of Stroke Clinical Research Conducted on Non-invasive Vagus Nerve Stimulation (nVNS) for the Acute Trea...

ECOR Stock Alert: Why Is electroCore Soaring Today?

electroCore skyrocketed today after the FDA gave its PTSD treatment a breakthrough designation. ECOR stock closed up 60% on the news!

3 Top Penny Stocks to Add to Your Watchlist in Mid-January

Which penny stocks are you watching right now? The post 3 Top Penny Stocks to Add to Your Watchlist in Mid-January appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols: SWNTAL

ElectroCore's Vagus Nerve Stimulator Wins Breakthrough Device Tag For Stress Disorder

The FDA has granted Breakthrough Designation to ElectroCore Inc's (NASDAQ:ECOR) gammaCore nVNS device for posttraumatic stress disorder (PTSD). The device showed a reduction of symptoms of PTSD by 31% w...

gammaCore™ Non-Invasive Vagus Nerve Stimulation(nVNS) Receives Breakthrough Device Designation for Treatment of Postt...

nVNS reduces symptoms of PTSD by 31% in sham-controlled study nVNS reduces symptoms of PTSD by 31% in sham-controlled study

ElectroCore's Non-invasive Nerve Stimulator Effective Against Migraine

ElectroCore Inc (NASDAQ: ECOR) announced the publication of a peer-reviewed paper entitled "Non-invasive vagus nerve stimulation (nVNS) for the prevention of migraine" in Cephalalgia, the official journ...

electroCore Announces Publication of PREMIUM II Trial of gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) for t...

ROCKAWAY, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer-reviewed paper, entitled ...

electroCore, Inc. Provides Update on Global Distribution Partners

ROCKAWAY, NJ, Dec. 16, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced it has entered into agreements with ...

electroCore, Inc. Announces The Launch of a New Online Shop in the United Kingdom

ROCKAWAY, NJ, Dec. 15, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced the launch of an e-commerce shop for...

electroCore, Inc. Provides Update on nVNS to Treat Post Traumatic Stress Disorder

ROCKAWAY, NJ, Dec. 14, 2021 (GLOBE NEWSWIRE) --  electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today provided an update on the ongoing clinical re...

electroCore Announces New Patent for Stroke and TIA Treatment

ROCKAWAY, NJ, Dec. 13, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Tr...

5 Stocks Insiders Are Still Buying (Even As Others Cash Out)

Insider sales are generally a sign the market is about to drop, but not everyone's selling. Here are five companies with insider buying.

Other symbols: BALYATECTCON

electroCore to Participate at Canaccord Genuity MedTech & Diagnostics Forum

ROCKAWAY, NJ, Nov. 11, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will be ava...

electroCore Announces Third Quarter 2021 Financial Results

Third quarter 2021 revenue grew 17% sequentially and 38% over third quarter 2020